Trial Profile
Phase I dose-escalation study of the orally administrered selective Bcl-2 inhibitor S055746 as monotherapy for the treatment of patients with Acute Myeloid Leukaemia (AML) or high or very high risk Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 10 Oct 2022
Price :
$35
*
At a glance
- Drugs Servier 1 (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions
- Sponsors IRIS
- 22 Oct 2018 Status changed from active, no longer recruiting to completed.
- 02 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 25 Jun 2017 Preliminary results (n=34; Data cut off:23 February 2017) presented at the 22nd Congress of the European Haematology Association